The in silico child

Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy

Stephanie Läer, Jeffrey S. Barrett, Bernd Meibohm

Research output: Contribution to journalReview article

52 Citations (Scopus)

Abstract

Significant gains have been made in the appreciation of pediatrics as an important population in which rationale pharmacotherapy guidance is warranted but often currently lacking. Although the regulatory framework for major improvements in pediatric drug development was implemented in Europe a decade later than the United States, recent efforts, including the 2007 ĝ€?Better Medicines for Childrenĝ€? initiative, indicate that the awareness of this problem is indeed a global phenomenon. Nevertheless, there still remains a gap between the awareness and the implementation of rationale and scientifically based drug development and applied pharmacotherapy in children. Specifically, a vision of how best to move from empiricism toward a plan that incorporates biologic knowledge about the maturation of physiologic processes as well as the drug- and disease-specific knowledge generated from drug development and applied pharmacotherapy in adults must evolve from the present intentions. Modeling and simulation approaches can facilitate such a vision that ultimately should provide benefit to pediatric patients. Although recent examples of pediatric in silico approaches are compelling, their ultimate value may be in the identification of data and studies that better guide drug therapy and in the education of pediatric caregivers to the principles of clinical pharmacology that underlie optimal pharmacotherapeutic decisions in children.

Original languageEnglish (US)
Pages (from-to)889-904
Number of pages16
JournalJournal of Clinical Pharmacology
Volume49
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Computer Simulation
Pediatrics
Drug Therapy
Pharmaceutical Preparations
Empiricism
Clinical Pharmacology
Caregivers
Education
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology

Cite this

The in silico child : Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. / Läer, Stephanie; Barrett, Jeffrey S.; Meibohm, Bernd.

In: Journal of Clinical Pharmacology, Vol. 49, No. 8, 08.2009, p. 889-904.

Research output: Contribution to journalReview article

@article{6a658d9d44ee4a0dae4dc1d3c863a79f,
title = "The in silico child: Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy",
abstract = "Significant gains have been made in the appreciation of pediatrics as an important population in which rationale pharmacotherapy guidance is warranted but often currently lacking. Although the regulatory framework for major improvements in pediatric drug development was implemented in Europe a decade later than the United States, recent efforts, including the 2007 ĝ€?Better Medicines for Childrenĝ€? initiative, indicate that the awareness of this problem is indeed a global phenomenon. Nevertheless, there still remains a gap between the awareness and the implementation of rationale and scientifically based drug development and applied pharmacotherapy in children. Specifically, a vision of how best to move from empiricism toward a plan that incorporates biologic knowledge about the maturation of physiologic processes as well as the drug- and disease-specific knowledge generated from drug development and applied pharmacotherapy in adults must evolve from the present intentions. Modeling and simulation approaches can facilitate such a vision that ultimately should provide benefit to pediatric patients. Although recent examples of pediatric in silico approaches are compelling, their ultimate value may be in the identification of data and studies that better guide drug therapy and in the education of pediatric caregivers to the principles of clinical pharmacology that underlie optimal pharmacotherapeutic decisions in children.",
author = "Stephanie L{\"a}er and Barrett, {Jeffrey S.} and Bernd Meibohm",
year = "2009",
month = "8",
doi = "10.1177/0091270009337513",
language = "English (US)",
volume = "49",
pages = "889--904",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - The in silico child

T2 - Using simulation to guide pediatric drug development and manage pediatric pharmacotherapy

AU - Läer, Stephanie

AU - Barrett, Jeffrey S.

AU - Meibohm, Bernd

PY - 2009/8

Y1 - 2009/8

N2 - Significant gains have been made in the appreciation of pediatrics as an important population in which rationale pharmacotherapy guidance is warranted but often currently lacking. Although the regulatory framework for major improvements in pediatric drug development was implemented in Europe a decade later than the United States, recent efforts, including the 2007 ĝ€?Better Medicines for Childrenĝ€? initiative, indicate that the awareness of this problem is indeed a global phenomenon. Nevertheless, there still remains a gap between the awareness and the implementation of rationale and scientifically based drug development and applied pharmacotherapy in children. Specifically, a vision of how best to move from empiricism toward a plan that incorporates biologic knowledge about the maturation of physiologic processes as well as the drug- and disease-specific knowledge generated from drug development and applied pharmacotherapy in adults must evolve from the present intentions. Modeling and simulation approaches can facilitate such a vision that ultimately should provide benefit to pediatric patients. Although recent examples of pediatric in silico approaches are compelling, their ultimate value may be in the identification of data and studies that better guide drug therapy and in the education of pediatric caregivers to the principles of clinical pharmacology that underlie optimal pharmacotherapeutic decisions in children.

AB - Significant gains have been made in the appreciation of pediatrics as an important population in which rationale pharmacotherapy guidance is warranted but often currently lacking. Although the regulatory framework for major improvements in pediatric drug development was implemented in Europe a decade later than the United States, recent efforts, including the 2007 ĝ€?Better Medicines for Childrenĝ€? initiative, indicate that the awareness of this problem is indeed a global phenomenon. Nevertheless, there still remains a gap between the awareness and the implementation of rationale and scientifically based drug development and applied pharmacotherapy in children. Specifically, a vision of how best to move from empiricism toward a plan that incorporates biologic knowledge about the maturation of physiologic processes as well as the drug- and disease-specific knowledge generated from drug development and applied pharmacotherapy in adults must evolve from the present intentions. Modeling and simulation approaches can facilitate such a vision that ultimately should provide benefit to pediatric patients. Although recent examples of pediatric in silico approaches are compelling, their ultimate value may be in the identification of data and studies that better guide drug therapy and in the education of pediatric caregivers to the principles of clinical pharmacology that underlie optimal pharmacotherapeutic decisions in children.

UR - http://www.scopus.com/inward/record.url?scp=70349271378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349271378&partnerID=8YFLogxK

U2 - 10.1177/0091270009337513

DO - 10.1177/0091270009337513

M3 - Review article

VL - 49

SP - 889

EP - 904

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8

ER -